Innovation at Work
New Hampshire

Research in the Granite State

**Dartmouth College, Hanover, NH**
Methicillin-resistant *Staphylococcus aureus* (MRSA) is responsible for approximately half of all drug-resistant bacteria-related deaths in the U.S. National Institutes of Health (NIH)-funded researchers at Dartmouth College are working to develop an enzyme that binds to and kills MRSA.

**Neurocrine Biosciences, Nashua, NH**
Neurocrine Biosciences is conducting phase II clinical trials to test the safety and efficacy of a new drug intended to treat Tourette’s syndrome. This neurological disorder affects an estimated 1 out of every 360 children between the ages of 6 and 17.

**ImmuNext and Janssen Biotech, Lebanon, NH**
ImmuNext and Janssen Biotech are collaborating to develop a new antibody treatment for advanced cancers. This treatment is now in phase I clinical trials to evaluate safety, assess a safe dosage range and identify side effects.

**Sources:** National Institutes of Health, Pharmaceutical Research and Manufacturers of America (PhRMA), Centers for Disease Control and Prevention, a Research!America survey of U.S. adults conducted in partnership with Zogby Analytics in June 2016, ImmuNext, ClinicalTrials.gov.